In-vitro immunomodulatory effects of nicotine on Nitric Oxide, interleukin 1β and interleukin 37 production in human peripheral blood mononuclear cells (PBMC) from patients with Behçet disease

Int Immunopharmacol. 2021 Dec;101(Pt A):108189. doi: 10.1016/j.intimp.2021.108189. Epub 2021 Oct 1.

Abstract

Behçet's disease is a chronic systemic inflammatory disorder associated with a cytokine profile disruption and increased nitric oxide levels. In our current study we sought to evaluate the in-vitro modulatory effect of nicotine, the principal alkaloid of tobacco, on nitric oxide (NO), interleukin 1β (IL-1β) and interleukin 37 (IL-37) production during Behçet's disease. Peripheral blood mononuclear cells cultures were performed with or without nicotine (200 μg/ml). Culture supernatants were harvested after 24 h of incubation. NO, IL-1β and IL-37 measurements were, respectively, performed by modified Griess method and ELISA sandwich. Our results showed that nicotine significantly reduced NO and IL-1β levels in patients with Behçet's disease, while it increased IL-37 production. Our results showed no sex differences in the effects of nicotine on the production of nitric oxide and IL-1β nor IL-37 in PBMC of patients. Our findings suggest that nicotine may provide a potential therapeutic strategy targeting inflammation during Behçet's disease.

Keywords: Anti-inflammatory effect; Behçet disease; Interleukin −37; Interleukin-1β; Nicotine; Nitric oxide.

MeSH terms

  • Adult
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / immunology
  • Female
  • Humans
  • Immunomodulating Agents / pharmacology*
  • Interleukin-1 / metabolism*
  • Interleukin-1beta / metabolism*
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Middle Aged
  • Nicotine / pharmacology*
  • Nitric Oxide / metabolism*
  • Young Adult

Substances

  • IL1B protein, human
  • IL37 protein, human
  • Immunomodulating Agents
  • Interleukin-1
  • Interleukin-1beta
  • Nitric Oxide
  • Nicotine